Darolutamide (Nubeqa) Gets OK in Europe for Prostate Cancer Darolutamide (Nubeqa) Gets OK in Europe for Prostate Cancer

It joins two other androgen receptor inhibitors for use in the treatment of nonmetastatic castration-resistant prostate cancer.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news